智翔金泰:2025年营收2.31亿元,净利润亏损收窄32.74%

Core Viewpoint - The company reported significant revenue growth for the fiscal year 2025, with total operating revenue reaching 230.72 million, a year-on-year increase of 666.65%. However, it also reported a net loss attributable to the parent company of 536.22 million, although this loss has narrowed by 32.74% compared to the previous year [1]. Financial Performance - Total operating revenue for 2025 was 230.72 million, reflecting a substantial increase of 666.65% year-on-year [1]. - The net profit attributable to the parent company was -536.22 million, indicating a reduction in losses by 32.74% [1]. - The non-recurring net profit was -579.22 million, with a loss reduction of 27.99% [1]. Asset and Equity Position - At the end of the reporting period, total assets amounted to 2,992.66 million, which represents a decrease of 4.87% year-on-year [1]. - The equity attributable to the parent company's owners was 1,584.20 million, showing a decline of 25.49% compared to the previous year [1]. Revenue Drivers - The growth in revenue and the narrowing of losses were primarily driven by an increase in product sales revenue and an uptick in licensing income [1].

Chongqing Genrix Biopharmaceutical -智翔金泰:2025年营收2.31亿元,净利润亏损收窄32.74% - Reportify